biocon semaglutide Set to Launch Weight-Loss Generic by 2027: CEO Insights, ETPharma Home - Liraglutide Biocon

While it is known that skin cells can produce estrogens locally, aromatase enzyme activity is dramatically reduced to approximately 30 times lower than in premenopausal ovarian follicular tissue [10]

there is not enough scientific data to prove their safety

Manufacturing Capacity and Supply Chain Investment: In a bid to avoid previous shortages of injectable GLP-1s, Eli Lilly has amassed a $1.5 billion pre-launch inventory of its oral weight loss drug orforglipron ahead of FDA decision expected in April 2026 [4]

That makes it effective for treating obesity and diabetes, but this boost in biological regulation seems to have plenty of other benefits too